These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15718335)

  • 41. Current and emerging first-line systemic therapies in clear cell renal cell carcinoma.
    Rini BI
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):115-117. PubMed ID: 29741511
    [No Abstract]   [Full Text] [Related]  

  • 42. Neoadjuvant chemotherapy with a combination of irinotecan and cisplatin in advanced gastric cancer--a case report.
    Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Kameda Y; Noguchi Y
    Hepatogastroenterology; 2000; 47(36):1575-8. PubMed ID: 11149004
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Chemotherapy of renal cell carcinoma: experimental study and clinical effect].
    Kanda H; Matsuura T; Akiyama T; Kurita T
    Hinyokika Kiyo; 1988 Nov; 34(11):1879-84. PubMed ID: 3242362
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.
    Fennell DA; Steele JP; Shamash J; Evans MT; Wells P; Sheaff MT; Rudd RM; Stebbing J
    Cancer; 2007 Jan; 109(1):93-9. PubMed ID: 17146783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
    Muggia FM; Blessing JA; McGehee R; Monk BJ
    Gynecol Oncol; 2004 Aug; 94(2):483-7. PubMed ID: 15297192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder.
    Kawahara T; Nishiyama H; Yamamoto S; Kamoto T; Ogawa O
    Int J Urol; 2006 Sep; 13(9):1251-3. PubMed ID: 16984565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose interleukin-2 in metastatic renal cell carcinoma.
    Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
    J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
    [No Abstract]   [Full Text] [Related]  

  • 48. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
    Escudier B
    J Clin Oncol; 2010 May; 28(13):2125-6. PubMed ID: 20368540
    [No Abstract]   [Full Text] [Related]  

  • 49. HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC.
    Ellerhorst JA; Hildebrand WH; Cavett JW; Fernandez-Vina MA; Hodges S; Poindexter N; Fischer H; Grimm EA
    Urologe A; 2004 Sep; 43 Suppl 3():S137. PubMed ID: 15148575
    [No Abstract]   [Full Text] [Related]  

  • 50. [Irinotecan].
    Yokoyama A
    Nihon Rinsho; 2002 May; 60 Suppl 5():339-42. PubMed ID: 12101684
    [No Abstract]   [Full Text] [Related]  

  • 51. Metastatic renal cell carcinoma: systemic treatment.
    Abi-Aad AS; deKernion JB
    Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
    [No Abstract]   [Full Text] [Related]  

  • 52. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Entropy increases in kidney cancer treatment, but a bit of simplicity may emerge from chaos.
    Porta C
    Eur Urol; 2011 Dec; 60(6):1171-2. PubMed ID: 21820238
    [No Abstract]   [Full Text] [Related]  

  • 54. Chemotherapeutic strategies for renal cell carcinoma.
    Milowsky MI; Nanus DM
    Urol Clin North Am; 2003 Aug; 30(3):601-9, x. PubMed ID: 12953758
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coumarin plus cimetidine: yet another angle for therapy of renal cell carcinoma.
    Kirkwood JM; Ernstoff MS
    J Clin Oncol; 1987 Jun; 5(6):836-7. PubMed ID: 3585440
    [No Abstract]   [Full Text] [Related]  

  • 56. Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates.
    Maiti A; Brown RE; Corn PG; Murthy R; Ganeshan DM; Tsimberidou AM; Subbiah V
    Clin Genitourin Cancer; 2016 Apr; 14(2):e187-93. PubMed ID: 26684814
    [No Abstract]   [Full Text] [Related]  

  • 57. [Chemotherapy of renal cell carcinoma. II. Adriamycin and carboquone combined chemotherapy].
    Osawa T
    Nihon Hinyokika Gakkai Zasshi; 1986 Nov; 77(11):1805-13. PubMed ID: 3573463
    [No Abstract]   [Full Text] [Related]  

  • 58. Renal cell carcinoma: trying but failing to improve the only curative therapy.
    Acquavella N; Fojo T
    J Immunother; 2013; 36(9):459-61. PubMed ID: 24145356
    [No Abstract]   [Full Text] [Related]  

  • 59. The National Institute of Health and Clinical Excellence rejects new treatments for renal cell cancer: Cinderella's invitation is cancelled.
    Eisen T
    BJU Int; 2008 Dec; 102(11):1491-2. PubMed ID: 19007367
    [No Abstract]   [Full Text] [Related]  

  • 60. New approaches to the evaluation of the metastatic ability of renal cancer and new approaches to chemotherapy.
    Isaacs WB; Isaacs JT; Kyprianou N; Burgers JK; Alexander RB; Partin AW; Mohler JL; Marshall FF; Coffey DS
    Eur Urol; 1990; 18 Suppl 2():33-5. PubMed ID: 2226604
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.